PEGASUS-1 : Perampanel for the control of glioma associated seizures – efficacy and safety: a pilot phase II randomised controlled trial

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18-65Age 18-65

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Side effects,Systemic therapy | Brain and spinal cordBrain,Glioblastoma (GBM) ,Glioma

Trial Overview Read MoreRead more

This phase II trial is evaluating an anti-epileptic drug as a way of controlling seizures in patients being treated for grade II-III gliomas.
 

This trial is treating patients with grade II-III gliomas.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Perampanel for the control of glioma associated seizures – efficacy and safety: a pilot phase II randomised controlled trial

Other Non-Commercial Sponsor

Royal Melbourne Hospital

Summary

This is a randomised clinical trial, in which patients, will be post-operatively randomised to receive either perampanel or levetiracetam for 52 weeks.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next